Zami Aberman
2019
In 2019, Zami Aberman earned a total compensation of $1.1M as Executive Chairman at Pluristem Therapeutics, a 85% increase compared to previous year.
Compensation breakdown
| Salary | $551,137 |
|---|---|
| Stock Awards | $478,500 |
| Other | $66,857 |
| Total | $1,096,494 |
Aberman received $551.1K in salary, accounting for 50% of the total pay in 2019.
Aberman also received $478.5K in stock awards and $66.9K in other compensation.
Rankings
In 2019, Zami Aberman's compensation ranked 8,852nd out of 13,971 executives tracked by ExecPay. In other words, Aberman earned more than 36.6% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 8,852 out of 13,971 | 37th |
Division Manufacturing | 3,532 out of 5,701 | 38th |
Major group Chemicals And Allied Products | 1,338 out of 2,200 | 39th |
Industry group Drugs | 1,139 out of 1,886 | 40th |
Industry Biological Products, Except Diagnostic Substances | 257 out of 389 | 34th |
Source: SEC filing on May 20, 2020.
Aberman's colleagues
We found three more compensation records of executives who worked with Zami Aberman at Pluristem Therapeutics in 2019.
News
Pluristem Therapeutics CEO Yaky Yanay's 2022 pay falls 86% to $1.3M
February 27, 2023
Pluristem Therapeutics Chairman Zami Aberman's 2020 pay falls 54% to $501K
April 8, 2021
Pluristem Therapeutics Chairman Zami Aberman's 2019 pay jumps 85% to $1.1M
May 20, 2020
Pluristem Therapeutics CEO Zami Aberman's 2018 pay falls 83% to $593K
April 25, 2019